Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy
At a glance
Conditions
NCT03610906
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Children's Hospital Colorado
Aurora, Coloradono site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Todd Hankinson, MD · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Identification of Potential Therapeutic TargetsBeginning of study to end of study, up to 1 year.
Investigators will identify potential therapeutic targets through mRNA expression.
- Identification of Potential Therapeutic TargetsBeginning of study to end of study, up to 1 year.
Investigators will identify potential therapeutic targets through microarray analysis.
- Identification of Potential Therapeutic TargetsBeginning of study to end of study, up to 1 year.
Investigators will identify potential therapeutic targets immunohistochemistry.
- Identification of Potential Therapeutic TargetsBeginning of study to end of study, up to 1 year.
Investigators will identify potential therapeutic targets through quantitative PCR.
- Identification of Potential Therapeutic TargetsBeginning of study to end of study, up to 1 year.
Investigators will also perform immunostaining for beta-catenin and use DNA SNaPshot analysis to determine what parts of the tumor are responsible for observed gene signatures.